← ANAVEX LIFE SCIENCES CORP. (AVXL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ANAVEX LIFE SCIENCES CORP. (AVXL)
Biological Products, (No Diagnostic Substances) · market cap $216M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-24 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Anavex Life Sciences (AVXL) is a clinical-stage biotech with a market cap of ~$250M focused on its lead asset ANAVEX2-73, a small molecule in Phase 3 development for Alzheimer's Disease, Rett Syndrome, and Parkinson's Disease with Dementia, plus a Phase 2 program in Schizophrenia. The company holds $131.7M in cash with a runway of approximately 55 months, providing meaningful buffer to read out multiple late-stage trials without near-term dilution pressure.
The catalyst path
- 2026-11-24 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ANAVEX2-73 | Phase 3 | Alzheimer's Disease |
| Mid dose ANAVEX2-73 | Phase 3 | Alzheimer Disease |
| ANAVEX2-73 Oral | Phase 2 | Alzheimer's Disease |
| ANAVEX2-73 oral liquid | Phase 3 | Rett Syndrome |
| ANAVEX3-71 oral capsules | Phase 2 | Schizophrenia |
| High dose ANAVEX2-73 | Phase 3 | Parkinsons Disease With Dementia |
Price & technical context
3-month
-33.8%
6-month
-41.1%
12-month
-80.5%
52-wk range
$1.76–$9.96
vs 50-day MA
-37.2%
vs 200-day MA
-47.4%
Realized vol
95.5%
Max drawdown
-86.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AVXL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.